Product Information

Registration Status: Active

KANARB TABLET 120MG is approved to be sold in Singapore with effective from 2017-04-24. It is marketed by ZUELLIG PHARMA PTE LTD, with the registration number of SIN15222P.

This product contains Fimasartan 120mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by BORYUNG PHARMACEUTICAL CO. in KOREA, and LTD in REPUBLIC OF.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea in September 9th, 2010 and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership.


Used for the treatment of hypertension and heart failure [A20319].

Mechanism of Action

Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors [A20319, T28]. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules [T28]. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect.


Tmax is 0.5-1.3 h [A20319].

Active Ingredient/Synonyms

Fimasartan | Fimasartan |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank